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Malignant pleural mesothelioma (MPM) is a rare pleural disease with a poor prognosis. Currently
treatment options are limited and the outcome is generally quite poor.
We report the case of a 76-year-old man diagnosed with locally advanced MPM who had partial
spontaneous response for 2 years and remained asymptomatic for more than 3 years. The
patient was taking speciﬁc herbal and vegetable diet during the course of response.
In our review of literature, a number of prognostic factors predict for better survival and
response. However our patients did not have any of these factors. There have been reports of
immune-induced responses in the literature. Our patient did indeed use some herbal products
that might interfere with the immune system and explain his tumour regression and long period
of disease stability. Further analyses and studies are needed in this setting to explore and
identify speciﬁc immune pathways and targets to develop more effective treatment for MPM.
& 2015 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Malignant pleural mesothelioma (MPM) is an aggressive tumour
with a poor prognosis predominantly arising from the pleura.
It is usually strongly associated with past exposure to asbestos
[1]. Treatment options for patients with MPM include surgery,
radiotherapy and/or chemotherapy [2,3]. Selected patients.02.002
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alone or in combination with chemotherapy and radiation
therapy and could have a median survival of up to 2 years [4].
Prolonged disease-free periods are quite rare and only few
cases of partial or complete spontaneous regression have been
reported in the literature. A recent literature review could
only ﬁnd 5 reported cases of spontaneous regression of a
primary thoracic malignancy [5]. MPM tumours are thought to
be immunogenic based on animal studies and the good
responses in some humans treated with immunotherapy. Some
data reported suggest that spontaneous regression may be an
immune-mediated phenomenon [6–8].erved.
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We report the case of a 76-year-old gentleman diagnosed
with an MPM. He has a history of hypertension, stage II
chronic kidney disease and benign prostate hypertrophy. In
addition he worked previously as a millwright with a high
likelihood of occupational asbestos exposure and has
smoked 5 pack-years but quit over 50 years ago.
He presented with mild intermittent pain in the left rib
cage mostly on exertion, with no shortness of breath, fever
or traumatic injury. The persistent pain prompted a chest
X-ray, which at the time revealed no overt abnormalities.
Two months later, due to non-resolution of symptoms, a CT
of the chest was performed revealing asymmetric left
pleural effusion and thickening (Figure 1a, b); further
staging, including a CT of the abdomen+pelvis as well as
a bone scan, did not reveal distant disease. An initial
diagnostic and therapeutic thoracocentesis was positive
for malignancy. The ﬂuid contained groups of large cells in
a background of acute and chronic inﬂammatory cells.
Nuclear atypia with irregular nuclear membrane and fre-
quent mitotic ﬁgures were seen. Immunostaining was posi-
tive for CK5/6, WT1, calretinin and negative for TTF1,
CK20, CDX2, ER, BerEp4 suggestive of atypical mesothelial
proliferation, favouring malignant mesothelioma. The com-
plete blood work was normal. Of note the neutrophils to
lymphocytes ratio (NLR) was 4.6. A conﬁrmatory left pleural
biopsy was also performed, revealing evidence of MPM (CK7
+, CK5/6+, TTF1, CK20, CD15, CEA, P63).
Following the thoracocentesis, the patient became asymp-
tomatic. His pulmonary tests were adequate. Although a
trimodality approach (surgery, radiotherapy, and chemother-
apy) was discussed, he was not deemed ﬁt for surgery due to
substantial risk of cardiovascular morbidity. Therefore, radia-
tion and chemotherapy were discussed; however, the patient
declined treatment and an active surveillance was initiated
with close follow-ups including consults, physical exam and
staging CTs every four to six months.
Beside his usual medications for hypertension, kidney
disease, and prostate, the patient started taking variousFigure 1 Chest CT images (coronal, upper row; axial, lower row
pleural thickening (arrows) and a small left pleural effusion were no
d) and (e, f) 24-month follow up studies, with increasing pleural inv
up, there was signiﬁcant decrease of left pleural disease, consisten
mild progression of the pleural disease was noted again (i, j) (arroherbal supplements after his diagnosis. These included daily
consumption of Chaga mushroom tea (one cup), a vegetable
drink that consists of asparagus, kale, Italian parsley and
watercress (one cup), Gyokuro green tea (one cup), sele-
nium (200 mcg), vitamin C (2 g) and D (4000 units).
In the ﬁrst year of surveillance, CT scans showed a mild
progression in the pleural disease with no metastases in
keeping with a stable disease as deﬁned by the RECIST
criteria version 1.1 (Figure 1c–f). The NLR was less than
3 during the 1st year then increased during the 2nd year
(44). Approximately two years after presentation, the
pleural thickening/effusion surprisingly improved consider-
ably and spontaneously (Figure 1g, h). This spontaneous
regression lasted for a year with signiﬁcant improvement in
functional status. The NLR decreased at the same time
approximately (o3). A regular follow up CT scan showed a
mild progression of the thickening once again while the
patient remained asymptomatic (Figure 1i, j). During the
whole period of surveillance, the patient had an ECOG
status of 0 and his daily consumption of the herbal products
cited was consistent. Subsequently after 3 years of surveil-
lance, the patient did progress on the CT Scan and became
symptomatic; the NLR again increased (44). He was started
on Platinum agent/Pemetrexed combination.3. Discussion
We present a case of a 76-year-old man with a conﬁrmed
MPM diagnosis that has spontaneous regression of his pleural
disease and remains highly functional for three years with-
out active medical treatment. The patient had a stable
disease as deﬁned by RECIST criteria during his surveillance
after the ﬁrst year followed by spontaneous partial
response. Few cases have been reported in the literature
regarding spontaneous remission of MPM and subsequent
long survival without treatment. Allen et al., reported a
case of a poorly differentiated epithelial mesothelioma that
regressed spontaneously, with the disease remaining in
remission for ﬁve years [9]. Other authors reported similar). At presentation, subtle focal areas of left paramediastinal
ted (a, b). Progression of disease was demonstrated in the 12 (c,
olvement (arrows) and pleural effusion. In the 30-month follow
t with spontaneous regression (g, h) (arrows). Six months after,
ws).
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addition, Higashiyama et al., had reported a case of a stage
IV epithelioid MPM patient that spontaneously regressed
after a local relapse following a pleurectomy, but had
recurred with slow growth after three years. This patient
self-administered an oral mushroom extract and underwent
a parasympathetic nerve stimulation therapy thought to
provide potential immune-modulation, after which he
experienced a high fever for two weeks with subsequent
tumour regression [12].
Retrospective analyses have been used to determine a
variety of prognostic factors in MPM potentially associated
with prolonged survival. Microscopic features associated
with long survival include innocuous nuclei, abundant
cytoplasm as well as large numbers of small lymphocytes
and scattered plasma cells [11,13]. MPM tumours of epithe-
lioid type, age less than 60 years old and female gender
were associated with a better prognosis in the German
register [14]. High MIB-1 proliferation index (Ki67) was
reported as a marker of worse prognosis [15]. Our patient
did not have many of these positive prognostic factors (male
gender, age greater than 60, microscopic features, Ki67 not
reported) despite his long survival without any active
treatment.
Furthermore, inﬂammation localised in the tumour has
been reported as a possible immune-mediated mechanism
of spontaneous regression. Thirty per cent of MPM patients
exhibit serological or immune reactivity to MPM antigens
[16]. The lymphohistiocytoid mesothelioma histologic sub-
type, known to have a better prognosis, is associated with
marked lymphocytic and plasmacytic inﬁltrate [17]. More-
over, some mesothelioma antigens were reported to have
disappeared or to be less expressed on relapse, an observa-
tion that is consistent with the immune reaction theory
[11]. Current concepts of MPM biology suggests that the
tumour is, to some extent, immunogenic [6] and clinical
trials investigating immunomodulatory agents have shown
evidence of response in a proportion of patients [7,8].
Lately, it was shown that PD-L1 is expressed in a substantial
number of MPM patients and was associated with poor
survival. With the development of drugs targeting PD-L1,
this may be an important research avenue for these
patients. On another hand, the NLR that reﬂects a systemic
inﬂammatory response has been recognised as a poor
prognostic marker in various cancers [18]. In our patient,
the NLR was elevated at diagnosis and its level varied with
the disease spontaneous response and progression. A mild
inﬂammation was present and reported on the pathology
favouring the immune-induced response hypothesis that
might explain the prolonged stability of his disease and
survival.
We acknowledge that our patient was on herbal products
that might have played a role or interfered in stabilizing the
disease or boosting the immune system against the tumour
cells. Animal model and in vitro research demonstrated that
curcumin might exhibit a variety of immunomodulating activ-
ities, including inhibition of growth and survival of T-lympho-
cytes, inhibition of antibody secretion by B-lymphocytes and
inhibit the production of pro-inﬂammatory cytokines, includ-
ing TNF-alpha and IL-1 [19,20]. Curcumin has also been shown
in cell lines to inhibit NF-kB and FGF-2-induced angiogenesis to
inhibit the proliferation of multiple cell lines [21,22]. Chagahas demonstrated antiproliferative effects in certain cancer
cell lines [23], and potential stimulation of aspects of humoral
immunity in in vitro studies [24]. Green tea contains numerous
polyphenols and catechins, which have been shown to induce
cell cycle arrest and apoptosis in many cancer cell lines [25],
and inhibit the activity of certain tyrosine kinase receptors
[26] (EGFR, HER2). Furthermore, it has been shown to
decrease tumour growth and metastases in mice models
[27]. However, such evidence cannot be extrapolated to
human studies, and it is unknown how these herbal products
may have affected the course of the patient's cancer.
An effective approach to investigate potential treatments
for MPM would be identifying MPM antigens and targeting
them with immune based therapies while overcoming the
tumour's ability to evade the immune system. Currently,
several trials are being conducted to investigate immu-
notherapy for the treatment of MPM, either as monotherapy
or in conjunction with standard treatments (NCT01843374,
NCT01265433, NCT01569919, NCT01583686).
4. Conclusion
In conclusion, spontaneous regression of MPM disease is a
rare occurrence, as reﬂected by the few cases reported in
the literature. It can be seen as a part of the spectrum of
the natural history of the disease or part of the individual
immune system targeting the tumour cells. Future research
aimed to understand the underlying immune mechanism of
MPM disease would help us develop more speciﬁc and potent
therapies.
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